BBIO — BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 725
- Website: https://www.bridgebio.com
Latest SEC filings for BBIO
- 8-K — 2026-08-10
- 10-Q — 2026-08-10
- SCHEDULE 13G/A — 2026-08-03
- S-8 — 2026-07-24
- S-3ASR — 2026-07-24
- S-3ASR — 2026-07-24
- 8-K — 2026-07-22
- SCHEDULE 13D/A — 2026-07-10
- 8-K — 2026-07-02
- 8-K — 2026-06-26
Latest BBIO news
- — 4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now (Zacks Investment Research)
- — BridgeBio: Maintaining 'Strong Buy' Additional Encaleret Data ADH1 And Three Expected FDA Reviews (seekingalpha.com)
- — Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records (GlobeNewswire Inc.)
- — BridgeBio reports improved symptoms in Phase 3 trial of rare-disease drug (seekingalpha_market)
- — Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1 (GlobeNewswire Inc.)
- — FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing (Zacks Investment Research)
- — BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026 (globenewswire.com)
- — BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting (globenewswire.com)
- — BridgeBio nabs Priority Review for infigratinib for achondroplasia (seekingalpha_market)
- — BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia (globenewswire.com)
Educational tool only — not investment advice.